The Massachusetts CFIDS/ME & FM Association, a 501(c)3 founded in 1985, exists to meet the needs of patients with CFIDS (Chronic Fatigue and Immune Dysfunction Syndrome, also known as Chronic Fatigue Syndrome), ME (Myalgic Encephalomyelitis) or FM (Fibromyalgia), their families and loved ones. The Massachusetts CFIDS/ME & FM Association works to educate health-care providers and the general public regarding these severely-disabling physical illnesses. We also support patients and their families and advocate for more effective treatment and research.
- Last Updated: 03 January 2016 03 January 2016
This group of articles, published in 2012 at various sources, evaluates status of commonly prescribed recommendations and treatments for Fibromyalgia.
"Fibro Doctors Chose Pfizer Over You "(Fibromyalgia Network, posted May 30, 2012) An editorial by Kristin Thorson, founder and editor of the Fibromyalgia Network, on the FibroCollaborative Roadmap for Change program. Disclaimer: This editorial is being provided as a source of information. The opinions expressed are those of the author and do not necessarily state or reflect the views of Massachusetts CFIDS/ME & FM Association.
"Fibro Out-of-Control?" (One of the free, sample articles available at Fibromyalgia Network) Dr. Charles Lapp and Dr. Carol Beals explain why FM symptoms get worse and offer ways to tackle.
"Increase in Diagnosis Rates and Penetration into New Markets Drives the Global Fibromyalgia Therapeutics Market, According to New Report by Global Industry Analysts, Inc." (PR Web) An article that takes a look at unmet medical needs for Fibromyalgia from a business standpoint.
"Low-Dose Naltrexone for Autoimmune Diseases and Fibromyalgia? The Unfinished Story" (ProHealth, Dec. 21, 2011)
“Milnacipran Beneficial for Fibromyalgia in Patients With Inadequate Response to Duloxetine” (Monthly Prescribing Reference (MPR) Review of two FM-specific medications (i.e., milnacipran (brand name, Savella) and duloxetine (brand name, Cymbalta) that includes study observations/ recommendations made by Dr. Lucinda Bateman at The Fatigue Consultation Clinic in Salt Lake City, UT.
"Omega-3 Trial Suggests 'a Nutritional Supplement Might Actually Make a Difference in Aging'" (ProHealth) An interesting article examining some of the benefits of supplemental omega-3 fatty acids as shown in a trial, "Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial," by Kiecolt-Glaser JK, et al. Ohio State University College of Medicine and College of Public Health; University of California, San Francisco, CA, published in Brain, Behavior, and Immunity, Sept. 23, 2012.
Notice about names
The Massachusetts CFIDS/ME & FM Association would like to clarify the use of the various acronyms for Chronic Fatigue Syndrome (CFS), Chronic Fatigue & Immune Dysfunction Syndrome (CFIDS) and Myalgic Encephalomyelitis (ME) on this site. When we generate our own articles on the illness, we will refer to it as ME/CFS, the term now generally used in the United States. When we are reporting on someone else’s report, we will use the term they use. The National Institutes of Health (NIH) are currently using ME/CFS. The Centers for Disease Control and Prevention (CDC) are calling the illness CFS.
Until there is consensus on a name for the illness, the Massachusetts CFIDS/ME & FM Association name will not change.